Navigation Links
Cadence Pharmaceuticals Appoints Stephen L. Newman, M.D., to its Board of Directors
Date:3/14/2013

SAN DIEGO, March 14, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today the appointment of Stephen L. Newman , M.D., to the company's board of directors.

"We are very pleased to welcome Dr. Newman to our board of directors. His experience in the evolving sector of integrated delivery networks, significant healthcare operations experience, and clinical background will be an invaluable addition to our board as we seek to expand our portfolio of products for use within the hospital setting," stated Cam Garner , Chairman of Cadence.

Dr. Newman served in positions of increasing responsibility with Tenet Healthcare Corporation (NYSE: THC), including as Vice Chairman from January 2012 until his retirement in June 2012. Since joining Tenet in 1999, he also served as Corporate Chief Operating Officer and Executive Vice President of Tenet Healthcare Corporation, Chief Executive Officer of Tenet HealthSystem, California, and as Senior Vice President, Gulf States Region, of Tenet HealthSystem. Prior to joining Tenet, Dr. Newman held executive positions at Columbia/HCA, Inc., and served as Senior Vice President and Chief Medical Officer of Touro Infirmary in New Orleans. Earlier in his career, Dr. Newman was an Associate Professor of Pediatrics and Medicine at Wright State University School of Medicine, and Director of Gastroenterology and Nutrition Support at Children's Medical Center in Dayton, Ohio.  Dr. Newman is currently a member of the Labor, Education and Healthcare Council of the Federal Reserve Bank of Atlanta, and a member of the Board of Directors of Optimer Pharmaceuticals, Inc. and Hansen Medical, Inc.  He holds a bachelor's degree from Rutgers University, an M.B.A. from Tulane University and a medical degree from the University of Tennessee. Dr. Newman completed his internship, residency and fellowship at Emory University School of Medicine, and has also completed the Advanced Management Program at the University of Pennsylvania's Wharton School of Business.

About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting. The current version of Cadence Pharmaceuticals' corporate overview may be viewed on the Investors page of www.cadencepharm.com under "Events & Presentations" by selecting "Corporate Overview."

CADENCE® and OFIRMEV® are registered trademarks of Cadence Pharmaceuticals, Inc.

 Contact:

William R. LaRue

Kelli FranceSVP & Chief Financial Officer

Media RelationsCadence Pharmaceuticals, Inc.

WCGPhone: 858-436-1400

Phone: 415-946-1076


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results
2. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Fourth Quarter And Full Year 2012 Financial Results On March 7, 2013
3. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013
4. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Leerink Swann Global Healthcare Conference In New York City On February 13, 2013
5. Cadence Pharmaceuticals Estimates Fourth Quarter 2012 Net Product Revenue and Provides Full Year 2013 Revenue Guidance
6. Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
7. Cadence Pharmaceuticals to Host Analyst and Investor Day
8. Cadence to Open Finished Medical Device Facility
9. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Piper Jaffray 24th Annual Healthcare Conference In New York City On November 28, 2012
10. Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results
11. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2012 Financial Results On November 5, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
Breaking Medicine News(10 mins):